Home » Bristol, ZymoGenetics Forge Interferon Deal
Bristol, ZymoGenetics Forge Interferon Deal
Bristol-Myers Squibb said it would pay tiny biotechnology company ZymoGenetics Inc $105 million to license, develop and sell its experimental new form of interferon to treat hepatitis C.
TradingMarkets
TradingMarkets
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May